Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome‐positive acute myeloid leukemia: A case report

Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome‐positive acute myeloid leukemia: A case report

Abstract Philadelphia chromosome‐positive acute myeloid leukemia (Ph + AML) is a rare type of AML with a low survival rate and poor prognosis. We first report a Ph + AML patient who remained in long‐term remission after the combination of flumatinib and venetoclax, which could provide corresponding...

Full description

Bibliographic Details
Main Authors:	Si‐Man Huang, Tao Tao, Chao‐Ling Wan, Tian‐Mei Wu, Han‐Yu Cao, Yan Qiu, Xiang‐Dong Shen, Bin‐Ru Wang, Shuai‐Shuai Ge, Yan‐Yan Li, Tong‐Tong Zhang, Bing Wu, Sheng‐Li Xue
Format:	Article
Language:	English
Published:	Wiley 2023-01-01
Series:	Clinical Case Reports
Subjects:	flumatinib Philadelphia chromosome‐positive acute myeloid leukemia regimen venetoclax
Online Access:	https://doi.org/10.1002/ccr3.6688

Similar Items

Basic and clinical study of efficacy and adverse effects of flumatinib in Ph+ ALL
by: Jun Wang, et al.
Published: (2023-05-01)

Combination of venetoclax with BCR-ABL tyrosine kinase inhibitor as a therapeutic strategy for Philadelphia chromosome-positive leukemias
by: Jing-Ying Zou, et al.
Published: (2023-12-01)

A Unique Three-Way Variant Philadelphia Chromosome t(6;9;22)(p21.3;q34;q11.2) in a Newly Diagnosed Patient with Chronic Myeloid Leukemia Responded to Flumatinib
by: Chen L, et al.
Published: (2022-09-01)

Venetoclax in adult acute myeloid leukemia
by: Mengci Hu, et al.
Published: (2023-12-01)

Efficacy and safety of switching to flumatinib in patients with chronic myeloid leukemia who have not achieved optimal response or are intolerant to TKI treatment
by: YANG Songfan, et al.
Published: (2024-02-01)

Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia
by: Bo Jiang, et al.
Published: (2023-02-01)

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
by: Sylvain Garciaz, et al.
Published: (2022-04-01)

BCR/ABL1 fluorescence <em>in situ</em> hybridization fusion signals on both copies of chromosome 22 in a Philadelphia-masked chronic myeloid leukemia case: implication for the therapy
by: Silvia Soriani, et al.
Published: (2021-03-01)

Venetoclax Resistance in Acute Myeloid Leukemia
by: Sylvain Garciaz, et al.
Published: (2024-03-01)

A case of acute lymphoblastic leukemia with additional chromosomes X and 5 associated with a Philadelphia chromosome in the bone marrow
by: Burak Durmaz, et al.
Published: (2010-12-01)

A case of acute lymphoblastic leukemia with additional chromosomes X and 5 associated with a Philadelphia chromosome in the bone marrow
by: Burak Durmaz, et al.
Published: (2010-12-01)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
by: Baohang Zhang, et al.
Published: (2023-05-01)

The Impact of Variant Philadelphia Chromosome Translocations on the Clinical Course of Chronic Myeloid Leukemia
by: Damla Eyüpoğlu, et al.
Published: (2016-02-01)

Phosphoproteomic Characterization and Kinase Signature Predict Response to Venetoclax Plus 3+7 Chemotherapy in Acute Myeloid Leukemia
by: Jie Jin, et al.
Published: (2024-03-01)

Studies on the inhibitory effect of isavuconazole on flumatinib metabolism in vitro and in vivo
by: Ya-nan Liu, et al.
Published: (2023-05-01)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
by: Zhangjie Chen, et al.
Published: (2023-03-01)

Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations
by: Anna Ferrari, et al.
Published: (2023-05-01)

Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial
by: Yifan Liu, et al.
Published: (2023-11-01)

Two Cases of Chronic Myeloid Leukemia in Lymphoid Blast Phase Presented as Philadelphia-Positive Acute Lymphoblastic Leukemia
by: Tae Hoon Lee, et al.
Published: (2023-10-01)

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting
by: Xubo Gong, et al.
Published: (2024-02-01)

“Preleukemic or smoldering” chronic myelogenous leukemia (CML):BCR-ABL1 positive: A brief case report
by: John M. Bennett, et al.
Published: (2015-01-01)

Chronic Myelogenous Leukemia with Double Philadelphia Chromosome and Coexpression of p210 and p190 Fusion Transcripts
by: Samara Silveira da Cruz, et al.
Published: (2022-03-01)

Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
by: Jorge Labrador, et al.
Published: (2022-03-01)

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
by: Xubo Gong, et al.
Published: (2023-06-01)

Research progress of anti-apoptotic inhibitor venetoclax in treatment of myeloid leukemia
by: XIANG Caixia, HUANG Bintao, HAO Jian
Published: (2023-05-01)

Chronic Myeloid Leukaemia : A paradigm for malignancy or just a strange disease?
by: Shaun R. McCann
Published: (2012-11-01)

A rare case of complex variant translocation of t(9;22;16)(q34;q11.2;q24) in a newly diagnosed patient with chronic myeloid leukemia
by: Bradley J. Grant, et al.
Published: (2022-01-01)

Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia
by: Tzu-Ting Chen, et al.
Published: (2024-03-01)

Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia
by: Mariarita Sciumè, et al.
Published: (2023-03-01)

Cannabis Extract Treatment for Terminal Acute Lymphoblastic Leukemia with a Philadelphia Chromosome Mutation
by: Yadvinder Singh, et al.
Published: (2013-11-01)

Artificial Intelligence Assisted Pharmacophore Design for Philadelphia Chromosome-Positive Leukemia with Gamma-Tocotrienol: A Toxicity Comparison Approach with Asciminib
by: Muhammad Naveed, et al.
Published: (2023-03-01)

Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of Resistance
by: Rahul Mishra, et al.
Published: (2023-12-01)

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
by: Louise Laloi, et al.
Published: (2023-03-01)

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults
by: Khalil Saleh, et al.
Published: (2022-04-01)

The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis
by: Yufeng Du, et al.
Published: (2023-12-01)

Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review
by: Chunmou Li, et al.
Published: (2022-12-01)

Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report
by: Yuina Akagi, et al.
Published: (2023-08-01)

Combined use of venetoclax and azacitidine in treatment of acute myeloid leukemia complicated with disseminated Fusarium infection: a case report
by: Guo Jun, Wei Pei, Tong Yajun, Chen Ting
Published: (2022-12-01)

Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience
by: Francesco Angotzi, et al.
Published: (2024-04-01)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
by: Xi Xu, et al.
Published: (2023-10-01)